103.31
前日終値:
$103.24
開ける:
$103.2
24時間の取引高:
1.74M
Relative Volume:
0.35
時価総額:
$19.62B
収益:
$3.08B
当期純損益:
$-986.58M
株価収益率:
-19.43
EPS:
-5.3172
ネットキャッシュフロー:
$292.08M
1週間 パフォーマンス:
-0.04%
1か月 パフォーマンス:
+0.86%
6か月 パフォーマンス:
+126.56%
1年 パフォーマンス:
+109.51%
Exact Sciences Corp Stock (EXAS) Company Profile
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EXAS
Exact Sciences Corp
|
103.31 | 19.61B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
501.62 | 189.66B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
206.39 | 150.27B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
626.17 | 50.25B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
123.90 | 35.58B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
321.47 | 31.72B | 3.17B | 642.63M | 539.81M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | ダウングレード | Mizuho | Outperform → Neutral |
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-03-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-08-28 | 開始されました | Wells Fargo | Overweight |
| 2024-06-27 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-01-02 | アップグレード | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 開始されました | Guggenheim | Buy |
| 2023-12-13 | 開始されました | Wolfe Research | Outperform |
| 2023-10-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-08-02 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2023-05-10 | アップグレード | Craig Hallum | Hold → Buy |
| 2023-05-05 | 開始されました | UBS | Neutral |
| 2023-03-09 | アップグレード | Citigroup | Neutral → Buy |
| 2023-02-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | ダウングレード | Craig Hallum | Buy → Hold |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Neutral |
| 2021-11-03 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 繰り返されました | BTIG Research | Buy |
| 2021-07-29 | 繰り返されました | Canaccord Genuity | Buy |
| 2021-07-29 | 繰り返されました | Oppenheimer | Outperform |
| 2021-07-29 | 繰り返されました | Stifel | Buy |
| 2021-06-15 | 開始されました | Raymond James | Strong Buy |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Equal Weight |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2020-10-29 | ダウングレード | UBS | Buy → Neutral |
| 2020-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-08 | 再開されました | BTIG Research | Buy |
| 2020-04-02 | 開始されました | Evercore ISI | Outperform |
| 2020-01-10 | 再開されました | BTIG Research | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-12-13 | 開始されました | Dougherty & Company | Buy |
| 2019-11-15 | 開始されました | Stifel | Buy |
| 2019-10-17 | 繰り返されました | BofA/Merrill | Buy |
| 2019-10-01 | 再開されました | Craig Hallum | Buy |
| 2019-09-26 | 開始されました | Oppenheimer | Outperform |
| 2019-02-26 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-09 | 開始されました | UBS | Buy |
| 2018-09-05 | 再開されました | The Benchmark Company | Hold |
| 2018-08-13 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2018-01-29 | 開始されました | Goldman | Neutral |
| 2018-01-08 | 繰り返されました | The Benchmark Company | Buy |
| 2017-11-13 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | ダウングレード | BTIG Research | Buy → Neutral |
すべてを表示
Exact Sciences Corp (EXAS) 最新ニュース
Exact Sciences (EXAS) Climbs to 2-Year High on Abbot Merger Reports - MSN
Exact Sciences Faces Rising Operational Risk and Strategic Constraints Amid Pending Abbott Merger - TipRanks
Key facts: Exact Sciences to merge with Abbott by Q2 2026; 2025 revenue up 18% - TradingView
Exact Sciences misses Q4 expectations for earnings, beats for revenue - Wisconsin State Journal
Illinois Municipal Retirement Fund Boosts Stake in Exact Sciences Corporation $EXAS - MarketBeat
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences (EXAS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Exact Sciences: Fourth Quarter Earnings Overview - Bitget
Exact Sciences: Q4 Earnings Snapshot - kens5.com
Exact Sciences (EXAS) Surpasses Q4 Revenue Expectations - GuruFocus
Exact Sciences Q4 Loss Narrows, Revenue Rises - marketscreener.com
EXACT SCIENCES CORP SEC 10-K Report - TradingView
Exact Sciences Corp. Reports Record Fourth Quarter and Full Year 2025 Results - TradingView
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results - Business Wire
Is It Too Late To Consider Exact Sciences (EXAS) After The US$105 Abbott Offer - Yahoo Finance
Mdxhealth to Present Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on February 26 - GlobeNewswire Inc.
Alger Mid Cap 40 ETF Q4 2025 Portfolio Update - Seeking Alpha
Exact Sciences Corporation (NASDAQ:EXAS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Take Profit: Will Exact Sciences Corporation benefit from green energy policiesLayoff News & Technical Buy Zone Confirmation - baoquankhu1.vn
Aug PreEarnings: Will Exact Sciences Corporation outperform its industry peersQuarterly Market Summary & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Allianz Asset Management GmbH Makes New Investment in Exact Sciences Corporation $EXAS - MarketBeat
Biotech operator Personalis sees 10% spike from Medicare covering lung cancer blood test - Mugglehead Magazine
Exact Sciences (NASDAQ:EXAS) Sets New 12-Month HighTime to Buy? - MarketBeat
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Northfield Bancorp Inc. (NasdaqNFBK), Coterra Energy Inc. (NYSECTRA), Exact Sciences Corporation (Nasdaq – EXAS), Semrush Holdings, Inc. (NYSE – - ChartMill
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings? - Yahoo Finance
Abbott to Buy Cancer-Screener Exact Sciences for $21 Billion - MSN
Exact Sciences Milestone In Breast Cancer Genomics And What It Means For EXAS - Yahoo Finance
PTAB Tosses 2nd Patent On Cologuard Colon Cancer Test - Law360
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences’ ’746 Patent - The AI Journal
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
The Truth About Exact Sciences Corp: Is This Cancer-Test Stock Quietly Going Viral or About to Flop? - AD HOC NEWS
Principal Financial Group Inc. Grows Position in Exact Sciences Corporation $EXAS - MarketBeat
C WorldWide Group Holding A S Has $46.97 Million Holdings in Exact Sciences Corporation $EXAS - MarketBeat
Exact Sciences Corporation $EXAS Shares Sold by Heritage Investors Management Corp - MarketBeat
Medicare coverage pathway established for multi-cancer detection tests By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Applauds Medicare Coverage Pathway for Can - GuruFocus
Medicare coverage pathway established for multi-cancer detection tests - Investing.com
Exact Sciences welcomes Medicare coverage pathway for multi-cancer tests - StreetInsider
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests - Business Wire
Exact Sciences (NASDAQ:EXAS) Hits New 12-Month HighShould You Buy? - MarketBeat
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Pa - GuruFocus
Exact Sciences stock hits 52-week high at $102.69 - Investing.com
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide - Business Wire
Multiple Tailwinds Lifted Exact Sciences Corporation (EXAS) in 2025 - Insider Monkey
Breast cancer test spares 1.6M from chemo, averages $10K lifetime savings - Stock Titan
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Bear Alert: Is Exact Sciences Corporation showing insider buyingWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
Abbott Laboratories Resets Portfolio With Exact Sciences Cancer Diagnostics Deal - Yahoo Finance UK
Freedom Capital Markets upgrades Abbott Labs stock rating to Buy on Exact Sciences deal - Investing.com
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Applied Materials, CDW, Exact Sciences, Harley-Davidson, Oshkosh, ServiceNow and More - AOL.com
Exact Sciences Corp (EXAS) 財務データ
収益
当期純利益
現金流量
EPS
Exact Sciences Corp (EXAS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Dec 23 '25 |
Option Exercise |
0.00 |
73,080 |
0 |
66,487 |
| Condella Sarah | EVP, Human Resources |
Dec 23 '25 |
Option Exercise |
0.00 |
47,208 |
0 |
118,059 |
| Herriott James | SVP, General Counsel & Sec |
Dec 23 '25 |
Option Exercise |
0.00 |
33,780 |
0 |
32,934 |
| Bloomer Aaron | EVP, Chief Financial Officer |
Dec 23 '25 |
Option Exercise |
0.00 |
63,099 |
0 |
59,571 |
| ORVILLE JACOB A | EVP, GM, Screening |
Nov 19 '25 |
Sale |
75.00 |
5,000 |
375,000 |
23,237 |
| Herriott James | SVP, General Counsel & Sec |
Nov 19 '25 |
Sale |
70.00 |
1,000 |
70,000 |
11,585 |
大文字化:
|
ボリューム (24 時間):